nach oben

Erschienen in:

01.06.2013 | Original Paper

Identification of thymosins β₄ and β₁₀ in paediatric craniopharyngioma cystic fluid

verfasst von: Claudia Desiderio, Claudia Martelli, Diana Valeria Rossetti, Concezio Di Rocco, Luca D’Angelo, Massimo Caldarelli, Gianpiero Tamburrini, Federica Iavarone, Massimo Castagnola, Irene Messana, Tiziana Cabras, Gavino Faa

Erschienen in: Child's Nervous System | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Adamantinomatous craniopharyngioma is the third most recurrent paediatric brain tumour. Although histologically benign, it behaves aggressively as a malignant tumour due to invasion of the hypothalamus and visual pathways. Surgery is still the first and almost the only mode of treatment, although serious damage can occur as a consequence of tumour localization. The proteomic characterization of the intracystic tumoural fluid could contribute to the comprehension of the tumorigenesis processes and to the development of therapeutic targets to reduce cyst volume, allowing less invasive surgery and/or delay of the radical resection of the tumour mass and the collateral serious effects.

Methods

Intracystic fluid was analysed by a LC-ESI-IT-MS top-down platform after acidification, deproteinization and chloroform liquid/liquid extraction.

Findings

Thymosin β₄ and β₁₀ peptides were for the first time identified in the intracystic fluid of adamantinomatous craniopharyngioma by low- and high-resolution MS analysis coupled with LC. The two peptides showed the same distribution trend in the analysed samples. Thymosin β₄ and β₁₀ were present in 77 % of the analysed samples. These peptides were not found in the cerebrospinal fluid available for two patients.

Interpretation

The presence of β-thymosins in the intracystic fluid of the tumour confirmed the secretion of these proteins in the extracellular environment. Due to their G-actin-sequestering activity and antiapoptotic and anti-inflammatory properties, these peptides could be strictly involved in both tumour progression and cyst development and growth.

Prabhu VC, Brown HG (2005) The pathogenesis of craniopharyngiomas. Child’s Nerv Syst 21:622–627CrossRef

Ahmadi J, Destian S, Apuzzo MLJ, Segall HD, Zee CS (1992) Cystic fluid in craniopharyngiomas: MR imaging and quantitative analysis. Radiology 182:783–785PubMed

Caldarelli M, Massimi L, Tamburrini G, Cappa M, Di Rocco C (2005) Long-term results of the surgical treatment of craniopharyngioma: the experience at the Policlinico Gemelli, Catholic University, Rome. Child’s Nerv Syst 21:747–757CrossRef

Thompson D, Phipps K, Hayward R (2005) Chraniopharyngioma in childhood: our evidence-based approach to management. Child’s Nerv Syst 21:660–668CrossRef

Cáceres A (2005) Intracavitary therapeutic options in the management of cystic craniopharyngioma. Child’s Nerv Syst 21:705–718CrossRef

Cavalheiro S, Dastoli PA, Silva NS, Toledo S, Lederman H, da Silva MC (2005) Use of interferon alpha in intratumoral chemotherapy for cystic craniopharyngioma. Child’s Nerv Syst 21:719–724CrossRef

Takahashi H, Yamaguci F, Teramoto A (2005) Long-term outcome and reconsideration of intracystic chemotherapy with bleomycin for craniopharyngioma in children. Child’s Nerv Syst 21:701–704CrossRef

Laffond C, Dellatolas G, Alapetite C, Puget S, Grill J, Habrand JL, Doz F, Chevignard M (2012) Quality-of-life, mood and executive functioning after childhood craniopharyngioma treated with surgery and proton beam therapy. Brain Inj 26:270–281PubMedCrossRef

Arefyeva A, Semenova JB, Zubairaev MS, Kondrasheva EA, Moshkin AV (2002) Analysis of fluid in craniopharyngioma-related cysts in children: proteins, lactate and pH. Acta Neurochir 144:551–554PubMedCrossRef

10.

Schaub C, Bluet-Pajot MT, Szikla G, Lornet-Videau C, Mounier F, Talairach J (1978) Distribution of beta2-microglobulin in cerebrospinal fluid and in cystic fluid of brain tumors. A preliminary study. Pathol Biol (Paris) 26:381–385

11.

Pettorini BL, Inizitari R, Massimi L, Tamburrini G, Caldarelli M, Fanali C, Cabras T, Messana I, Castagnola M, Di Rocco C (2010) The role of inflammation in the genesis of the cystic component of craniopharyngiomas. Child’s Nerv Syst 26:1179–1784

12.

Han X, Aslanian A, Yates JR III (2008) Mass spectrometry for proteomics. Curr Opin Chem Biol 12:483–490PubMedCrossRef

13.

Messana I, Cabras T, Iavarone F, Vincenzoni F, Urbani A, Castagnola M (2013) Unraveling the different proteomic platforms. J Sep Sci 36:128–139PubMedCrossRef

14.

Desiderio C, D’Angelo L, Rossetti DV, Iavarone F, Giardina B, Castagnola M, Massimi L, Tamburrini G, Di Rocco C (2012) Cerebrospinal fluid top-down proteomics evidenced the potential biomarker role of LVV- and VV-hemorphin-7 in posterior cranial fossa pediatric brain tumors. Proteomics 12:2158–2166PubMedCrossRef

15.

Hannappel E (2010) Thymosin β₄ and its posttranslational modifications. Ann N Y Acad Sci 1194:27–35PubMedCrossRef

16.

Inizitari R, Cabras T, Pisano E, Fanali C, Manconi B, Scarano E, Fiorita A, Paludetti G, Manni A, Nemolato S, Faa G, Castagnola M, Messana I (2009) HPLC-ESI-MS analysis of oral human fluids reveals that gingival crevicular fluid is the main source of oral thymosins β₄ and β₁₀. J Sep Sci 32:57–63CrossRef

17.

Honneger J, Mann K, Thierauf P, Zrinzo A, Fahlbusch R (1995) Human chorionic gonadotropin immunoreactivity in cystic intracanical tumors. Clin Endocrinol 42:235–241CrossRef

18.

Honneger J, Rennae C, Fahlbusch R, Adams EF (1997) Progesteron receptor gene expression in craniopharyngiomas and evidence for biological activity. Neurosurgery 41:1359–1364CrossRef

19.

Hannappel E (2007) β-thymosins. Ann N Y Acad Sci 1112:21–37PubMedCrossRef

20.

Sosne G, Qiu P, Goldstein AL, Wheater M (2010) Biological activities of thymosin β₄ defined by active sites in short peptide sequences. FASEB J 24:2144–2151PubMedCrossRef

21.

Mannherz HG, Hannappel E (2009) The β-thymosins: intracellular and extracellular activities of a versatile actin binding protein family. Cell Motil Cytoskel 66:839–851CrossRef

22.

Crockford D, Turyman N, Allan C, Angel J (2010) Thymosin β₄: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci 1194:179–189PubMedCrossRef

23.

Philp D, Kleinman HK (2010) Animal studies with thymosin β₄, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci 1194:81–86PubMedCrossRef

24.

Cha HJ, Jeong MJ, Kleinman HK (2003) Role of thymosin β₄ in tumor metastasis and angiogenesis. J Natl Cancer Inst 95:1674–1680PubMedCrossRef

25.

Huff T, Müller CSG, Otto AM, Netzker R, Hannappel E (2001) β-thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol 33:205–220PubMedCrossRef

26.

Smart N, Rossdeutsch A, Riley PR (2007) Thymosin β₄ and angiogenesis: modes of action and therapeutic potential. Angiogenesis 10:229–241PubMedCrossRef

27.

Sun LW, Lim H (2007) Neurotrophic roles of the beta-thymosins in the development and regeneration of nervous system. Ann N Y Acad Sci 1112:210–218PubMedCrossRef

28.

Van Kesteren RE, Carter C, Dissel HMG, JvMY G, Syed NI, Spencer GE, Smit AB (2006) Local of actin-binding protein beta-thymosin regulates neurite outgrowth. J Neurosci 26:152–157PubMedCrossRef

29.

Popoli P, Pepponi R, Martire A, Armida M, Pèzzola A, Galluzzo M, Domenici MR, Potenza RL, Tebano MT, Mollinari C, Merlo D, Garaci E (2007) Neuroprotective effects of thymosin beta4 in experimental models of excitotoxicity. Ann NY Acad Sci 1112:219–224PubMedCrossRef

30.

Hardesty WM, Kelley MC, Mi D, Low RL, Caprioli RM (2011) Protein signatures for survival and recurrence in metastatic melanoma. J Proteome 74:1002–1014CrossRef

31.

Kim NS, Kang YJ, Jo JO, Kim HY, Oh YR, Kim YO, Jung MH, Ock MS, Cha HJ (2011) Elevated expression of thymosin β₄, vascular endothelial growth factor (VEGF), and hypoxia inducible factor (HIF)-1α in early-stage cervical cancers. Pathol Oncol Res 17:493–502PubMedCrossRef

32.

Yoon SY, Lee HR, Park Y, Kim JH, Kim SY, Yoon SR, Lee WJ, Cho BJ, Min H, Bang JW, Park H, Bang SI, Cho D (2011) Thymosin β₄ expression correlates with lymph node metastasis through hypoxia inducible factor-α induction in breast cancer. Oncol Rep 25:23–31PubMed

33.

Wang ZY, Zeng FQ, Zhu ZH, Jiang GS, Lv L, Wan F, Dong R, Xyao XY, Xing SA (2012) Evaluation of thymosin β₄ in the regulation of epithelia–mesenchymal transformation in urothelial carcinoma. Urol Oncol 30:167–176PubMedCrossRef

34.

Xiao Y, Chen Y, Wen J, Yan W, Zhou K, Cai W (2012) Thymosin β₄: a potential molecular target for tumor therapy. Crit Rev Eukaryot Gene Expr 22:109–116PubMedCrossRef

35.

Ryu YK, Lee GH, Song KS, Kim YS, Moon EY (2012) Regulation of glycogen synthase kinase-3 by thymosin beta-4 is associated with gastric cancer cell migration. Int J Cancer 131:2067–2077PubMedCrossRef

36.

Can B, Karagoz F, Yildiz L, Yildirim A, Kefeli M, Gonullu G, Kandermir B (2012) Thymosin β₄ is a novel potential prognostic marker in gastrointestinal stromal tumors. APMIS 120:689–698PubMedCrossRef

37.

Goldestein AL (2003) Thymosin β₄: a new molecular target for antitumour strategies. J Natl Cancer Inst 95:1646–1647CrossRef

38.

Tang MC, Chan LC, Yeh YC, Chen YC, Chou TY, Wang WS, Su Y (2011) Thymosin β₄ induces colon cancer cell migration and clinical metastasis via enhancing ILK/IQGAP1/Rac1 signal transduction pathway. Cancer Lett 308:162–171PubMedCrossRef

39.

Cierniewski CS, Papiewska-Pajak I, Malinowski M, Sacewicz-Hofman I, Wiktorska M, Kryczka J, Wysocki T, Niewiarowska J, Bednarek R (2010) Thymosin β₄ regulates migration of colon cancer cells by a pathway involving interaction with Ku80. Ann N Y Acad Sci 1194:60–71PubMedCrossRef

40.

Zhang Y, Feurino LW, Zhai Q, Wang H, Fisher WE, Chen C, Yao Q, Li M (2008) Thymosin beta 4 is overexpressed in human pancreatic cancer cells and stimulates proinflammatory cytokine secretion and JNK activation. Cancer Biol Ther 7:419–423PubMedCrossRef

41.

Huang HC, Hu CH, Tang MC, Wang WS, Chen PM, Su Y (2007) Thymosin β₄ triggers an epithelial–mesenchymal transition in colorectal carcinoma by upregulating integrin-linked kinase. Oncogene 26:2781–2790PubMedCrossRef

42.

Lee H, Yoon SY, Song SB, Park Y, Kim TS, Kim S, Hur DY, Song HK, Park H, Cho D (2011) Interleukin-18-mediated interferon-gamma secretion is regulated by thymosin β₄ in human NK cells. Immunobiology 216:1155–1162PubMedCrossRef

43.

Qiu P, Kurpakus Wheater M, Qiu Y, Sosne G (2011) Thymosin β₄ inhibits TNF-α-induced NF-kB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK. FASEB J 25:1815–1826PubMedCrossRef

44.

Wang WS, Chen PM, Hsiao HL, Wang HS, Liang WY, Su Y (2004) Overexpression of the thymosin β-4 gene is associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma. Oncogene 23:6666–6671PubMedCrossRef

45.

Sekine S, Shibata T, Kokubu A, Morishita Y, Noguchi M, Nakanishi Y, Sakamoto M, Hirohashi S (2002) Chranipharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. Am J Pathol 161:1997–2001PubMedCrossRef

46.

Buslei R, Nolde M, Hofmann B, Meissner S, Eyupoglu IY, Siebzehnrubl F, Hahnen E, Kreutzer J, Fahlbusch R (2005) Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol 109:589–597PubMedCrossRef

47.

Gaston-Maussuet C, Andoniadou CL, Signore M, Jayakody SA, Charolidi N, Kyeyune R, Vernay B, Jacques TS, Taketo MM, Le Tissier P, Dattani MT, Martinez-Barbera JP (2011) Increased Wingless (Wnt) signaling in pituitary progenitor/stem cells gives rise to pituitary tumors in mice and humans. Proc Natl Acad Sci U S A 108:11482–11487CrossRef

48.

Cani CMG, Matushita H, Carvalho LRS, Soares IC, Brito LP, Almeida MQ, Mendonça BB (2011) PROP1 and CTNNB1expression in adamantinomatous craniopharyngiomas with or without β-catenin mutation. Clinics 66:1849–1854PubMed

49.

Andoniadou CL, Massuet CG, Reddy R, Schneider RP, Blasco MA, Le Tissier P, Jacque TS, Pevny LH, Dattani MT, Martinez-Barbera JP (2012) Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma. Acta Neuropathol 124:259–271PubMedCrossRef

50.

Nemolato S, Restivo A, Cabras T, Coni PP, Zorcolo L, Orrù G, Fanari M, Cau F, Gerosa C, Fanni D, Messana I, Castagnola M, Casula G, Faa G (2012) Thymosin β-4 in colorectal cancer is localized predominantly at the invasion front in tumor cells undergoing epithelial mesenchymal transition. Cancer Biol Ther 13:1–7CrossRef

51.

Faa G, Nemolato S, Cabras T, Fanni D, Gerosa C, Fanari M, Locci A, Fanos V, Messana I, Castagnola M (2012) Thymosin β₄ expression reveals intriguing similarities between fetal and cancer cells. Ann NY Acad Sci 1269:53–60PubMedCrossRef

52.

Castagnola M, Inzitari R, Fanali C, Iavarone F, Vitali A, Desiderio C, Vento G, Tirone C, Romagnoli C, Cabras T, Manconi B, Sanna MT, Boi R, Pisano E, Olianas A, Pellegrini M, Nemolato S, Heizmann CW, Faa G, Messana I (2011) The surprising composition of the salivary proteome of preterm human newborn. Mol Cell Proteomics 10:M110.003467PubMedCrossRef

53.

Sribenja S, Li M, Wongkham S, Wongkham C, Yao Q, Chen C (2009) Advances in thymosin β₁₀ research: differential expression, molecular mechanisms, and clinical implications in cancer and other conditions. Cancer Invest 20:1–7

54.

Kim YC, Kim BG, Lee JH (2012) Thymosin β₁₀ expression driven by the human TERT promoter induces ovarian cancer-specific apoptosis through ROS production. PLoS One 7:e35399. doi:10.1371/journal.pone.0035399 PubMedCrossRef

55.

Hannappel E, van Kampen M (1987) Determination of thymosin beta 4 in human blood cells and serum. J Chromatogr 397:279–285PubMedCrossRef

Titel: Identification of thymosins β4 and β10 in paediatric craniopharyngioma cystic fluid
verfasst von: Claudia Desiderio
Claudia Martelli
Diana Valeria Rossetti
Concezio Di Rocco
Luca D’Angelo
Massimo Caldarelli
Gianpiero Tamburrini
Federica Iavarone
Massimo Castagnola
Irene Messana
Tiziana Cabras
Gavino Faa
Publikationsdatum: 01.06.2013
Verlag: Springer-Verlag
Erschienen in: Child's Nervous System / Ausgabe 6/2013
Print ISSN: 0256-7040
Elektronische ISSN: 1433-0350
DOI: https://doi.org/10.1007/s00381-013-2069-9

Neu im Fachgebiet Chirurgie

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Recycling im OP – möglich, aber teuer

05.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO₂-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Im OP der Zukunft läuft nichts mehr ohne Kollege Roboter

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Identification of thymosins β₄ and β₁₀ in paediatric craniopharyngioma cystic fluid